CAJ | 학술논문

胆道系统肿瘤是一种较少见、预后差的恶性肿瘤.虽然化疗效果一直不佳,但是对于不能手术和术后复发的患者,化疗仍是治疗的基础.由于胆道肿瘤的遗传多态性、化疗方案的多样性和相对较小的研究样本,故胆道肿瘤化疗研究一直没有实质性的突破.虽然吉西他滨联合顺铂的化疗方案可显著延长患者的生存期,但目前尚缺乏有指导意义的化疗标准,仍需进一步深入研究.
담도계통종류시일충교소견、예후차적악성종류.수연화료효과일직불가,단시대우불능수술화술후복발적환자,화료잉시치료적기출.유우담도종류적유전다태성、화료방안적다양성화상대교소적연구양본,고담도종류화료연구일직몰유실질성적돌파.수연길서타빈연합순박적화료방안가현저연장환자적생존기,단목전상결핍유지도의의적화료표준,잉수진일보심입연구.
Biliary tract carcinoma is a rare cancer with poor prognosis.Although having limited clinical benefit,chemotherapy represents the cornerstone of management for patients with inoperable and postoperative recurrence of cholangiocarcinoma.Substantial breakthroughs in the study of chemotherapy for treatment in advanced cholangiocarcinoma are rare due to the heterogeneity of cholangiocarcinoma,the use of various chemotherapeutic agents and the small size of existing patient cohorts.Currently,no standard chemotherapeutic strategies exist for cholangiocarcinoma,though some combinatorial stratagies,such as gemcitabine plus cisplatin,have proven to prolong survival significantly.Still,further studies are needed to improve the treatment of patients with biliary tract cancer.